Tag: Immunotherapeutics
OSE Immunotherapeutics announces a collaboration agreement with GenDx for the development of a companion diagnostic test associated with Tedopi®, its epitope-based cancer vaccine candidate – 11/21/2023 at 6:00 p.m.
• A development program to support the next pivotal confirmatory phase 3 clinical trial currently being prepared.• A companion diagnostic test to identify HLA-A*02 positive cancer patients eligible for treatment…
OSE Immunotherapeutics enters into collaboration agreement with GenDx
By Alexandra Saintpierre Published on 11/21/2023 at 6:12 p.m. (Boursier.com) — OSE Immunotherapeutics SA announces a collaboration agreement…
OSE Immunotherapeutics joins forces with GenDx for the clinical trial of its anti-cancer vascin – 11/21/2023 at 6:13 p.m.
(AOF) – OSE Immunotherapeutics announced a collaboration agreement with GenDx (Eurobio Scientific Group, a key player in the field of in vitro diagnostics). This will involve developing and validating a…
OSE Immunotherapeutics: positive results against solid tumors
(AOF) – OSE Immunotherapeutics announces the presentation of the first phase 1 clinical results of BI 770371, a new anti-SIRPα monoclonal antibody evaluated in solid tumors, at the ESMO (European…
OSE Immunotherapeutics on the rise after positive results against cancer – 10/16/2023 at 09:40
(AOF) – OSE Immunotherapeutics (+11.57% to 4.87 euros) leads the SRD market after publishing the first positive results of the Phase 1/2 clinical trial evaluating OSE-279, its monoclonal antibody in…
OSE Immunotherapeutics announces its 2023 half-year results and provides an update on its progress – 09/27/2023 at 6:00 p.m.
Main financial elements • Financial visibility assured for the next 12 months, i.e. until the 4th quarter of 2024, supported by additional financing secured in the 1st half of 2023…
OSE Immunotherapeutics accentuates its losses in the first half of 2023
(AOF) – OSE Immunotherapeutics announces that as of June 30, 2023, its available cash flow amounted to 15 million euros, ensuring financial visibility until the fourth quarter of 2024. In…
OSE Immunotherapeutics accentuates its losses in the first half of 2023 – 09/27/2023 at 6:18 p.m.
(AOF) – OSE Immunotherapeutics announces that as of June 30, 2023, its available cash flow amounted to 15 million euros, ensuring financial visibility until the fourth quarter of 2024. In…
OSE Immunotherapeutics presents advances in its research programs at upcoming international conferences CICON International Conference (Cancer Immunotherapy Conference) SITC Congress (Society for Immunotherapy of Cancer) PEGS Europe (Protein & Antibody Engineering Summit) – 09/20/2023 at 07 :30
Nantes, France – September 20, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the scientific advances from its research programs have been selected for presentation…
OSE Immunotherapeutics: publication of positive phase 3 results of its anti-cancer vaccine – 09/12/2023 at 09:20
(Photo credits: Pixabay – fernando zhiminaicela) (AOF) – OSE Immunotherapeutics announces the publication of positive phase 3 results of its vaccine in patients with lung cancer resistant to immunotherapy in…
OSE Immunotherapeutics: publication of positive phase 3 results of its anti-cancer vaccine
(AOF) – OSE Immunotherapeutics announces the publication of positive phase 3 results of its vaccine in patients with lung cancer resistant to immunotherapy in the peer-reviewed journal “Annals of Oncology”.…
OSE Immunotherapeutics announces new public aid to support its innovation and research programs in the field of RNA Therapeutics – 08/01/2023 at 07:30
Nantes, France – August 1, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the Company has received innovation aid of 200,000 euros from the French…